FibroGen, Inc. (NASDAQ:FGEN) Files An 8-K Results of Operations and Financial Condition
Item 2.02
|
Results of Operations and Financial Condition. |
On May 9, 2017, FibroGen, Inc. (FibroGen) issued a press release
announcing financial results for the quarter ended March 31,
2017. A copy of such press release is furnished as Exhibit 99.1
to this report and is incorporated herein by reference.
The information in this Item 2.02, including Exhibit 99.1, shall
not be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that Section or Sections 11 and 12(a)(2) of the
Securities Act of 1933, as amended. The information contained in
this Item 2.02 and in Exhibit 99.1 shall not be incorporated by
reference into any filing with the U.S. Securities and Exchange
Commission made by FibroGen, whether made before or after the
date hereof, regardless of any general incorporation language in
such filing.
|
Item 9.01 |
Financial Statements and Exhibits. |
|
(d) |
Exhibits |
||
|
Exhibit No. |
Description |
||
|
99.1 |
Press Release titled FibroGen Reports First Quarter 2017 |
||
About FibroGen, Inc. (NASDAQ:FGEN)
FibroGen, Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200. FG-4592 is an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylases (HIF-PHs), which acts by stimulating the body’s natural pathway of erythropoiesis or red blood cell production. FG-4592 is in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). FG-3019 is a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, Duchenne muscular dystrophy (DMD) and liver fibrosis. FG-6874 is in Phase I clinical trials, and FG-5200 is a corneal implant medical device, which is in preclinical studies. FibroGen, Inc. (NASDAQ:FGEN) Recent Trading Information
FibroGen, Inc. (NASDAQ:FGEN) closed its last trading session up +0.50 at 27.80 with 467,634 shares trading hands.
